<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01181245</url>
  </required_header>
  <id_info>
    <org_study_id>FGCL-MC3019-028</org_study_id>
    <nct_id>NCT01181245</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer</brief_title>
  <official_title>A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FibroGen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FibroGen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives

        -  Primary: To evaluate the safety and tolerability of FG-3019 in combination with
           gemcitabine and erlotinib

        -  Secondary: To evaluate the efficacy and pharmacokinetics of FG-3019 in combination with
           gemcitabine and erlotinib
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of FG-3019 in combination with gemcitabine and erlotinib</measure>
    <time_frame>Through the end of the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>FG-3019 PK parameters</measure>
    <time_frame>Through the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>Through the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-month, 12-month and overall median survival rates</measure>
    <time_frame>Through the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal tumor response as determined by RECIST criteria</measure>
    <time_frame>Through the end of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Locally Advanced or Metastatic Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>FG-3019</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects are treated with FG-3019</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FG-3019</intervention_name>
    <description>3mg/kg IV, 10mg/kg IV, 15mg/kg IV, 25mg/kg, 35mg/kg IV, 45mg/kg IV - Biweekly, 35/17.5mg/kg, 45/22.5 mg/kg - Weekly</description>
    <arm_group_label>FG-3019</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Written informed consent

          2. Males and females aged â‰¥18 years old

          3. Histologically or cytologically confirmed adenocarcinoma of the pancreas

          4. Locally advanced (Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas

          5. Spiral CT scan demonstrating at least one pancreatic adenocarcinoma measurable lesion
             according to RECIST criteria and PET scan showing metabolically active lesion (for the
             last six subjects in the 15 mg/kg and the subjects in the 25 mg/kg FG-3019 dose
             cohorts only)

          6. Women of childbearing potential and men must use effective contraception during and
             for at least 90 days following study participation. Women of childbearing potential
             must have a negative Screening serum pregnancy test.

          7. ECOG performance status score of 0-1

          8. Life expectancy &gt;12 weeks

          9. Ability to adhere to the study visit schedule and understand and comply with all
             protocol requirements and instructions from study staff

        Exclusion Criteria

          1. Absolute neutrophil count (ANC) &lt;500 cells/mm3

          2. Hemoglobin &lt;10.0 g/dL

          3. Platelet count &lt;100,000 cells/mm3

          4. Bilirubin &gt;2.0 x upper limit of normal (ULN)

          5. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) &gt;2.5 x ULN, or
             &gt;3.5 x ULN if liver metastases are present

          6. If the subject is diabetic, HbA1c &gt;10%

          7. Current pregnancy or breast feeding due to recent pregnancy

          8. History of another malignancy in the past 2 years with the exception of basal cell or
             squamous cell carcinoma of the skin

          9. Previous chemotherapy with gemcitabine

         10. Previous systemic antineoplastic agent (other than adjuvant 5-fluorouracil as
             radio-sensitizer)

         11. Adjuvant 5-fluorouracil within 28 days prior to Day 1

         12. Major surgery within 28 days prior to Day 1 (stent placement is allowed)

         13. Radiation therapy within 28 days prior to Day 1

         14. Clinical evidence or any history of brain metastasis

         15. Uncontrolled hypertension (systolic blood pressure [SBP] &gt;180 mmHg or diastolic blood
             pressure [DBP] &gt;105 mmHg)

         16. New York Heart Association Class III or IV congestive heart failure

         17. History of allergic or anaphylactic reaction to human, humanized, or chimeric
             monoclonal antibodies

         18. Current clinical or laboratory evidence of active infection requiring antibiotic or
             antiviral therapy

         19. Active major gastrointestinal bleeding

         20. Full-dose heparin therapy within 28 days prior to Day 1

         21. Participation in studies of investigational products within 42 days prior to Day 1

         22. Clinically significant and uncontrolled medical condition considered a high risk for
             participation in an investigational study or a likelihood that the subject will be
             unable to comply with protocol requirements and complete the trial (e.g., emphysema
             requiring supplemental oxygen, poorly controlled arrhythmia, psychiatric illness,
             Alzheimer's disease)

         23. Current abuse of alcohol or drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert C Koong, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J. Marc Pipas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vincent J Picozzi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Mason Hospital/Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter J O'Dwyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Smitha Krishnamurthi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals of Cleveland, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles Lopez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nathan Bahary, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5152</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University (OHSU)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2009</study_first_submitted>
  <study_first_submitted_qc>August 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2010</study_first_posted>
  <last_update_submitted>August 4, 2014</last_update_submitted>
  <last_update_submitted_qc>August 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

